血管免疫母细胞性T细胞淋巴瘤治疗进展  

Advances. of treatment for angioimmunoblastic T-cell lymphoma

作　　者：周志远[1] 张明智[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《白血病．淋巴瘤》2013年第9期517-519,共3页Journal of Leukemia & Lymphoma

摘　　要：血管免疫母细胞性T细胞淋巴瘤（AITL）是一种罕见的侵袭性外周T细胞淋巴瘤，预后较差。AITL发病率较低，缺乏大样本的前瞻性临床随机对照试验，标准的治疗方案尚未明确。尽管以传统蒽环类药物为基础的化疗方案缓解率达50％，但大多数患者短期内复发，中位生存时间和总体生存率均不理想。最新研究发现造血干细胞移植、环孢素等治疗AITL显示出较好的临床疗效，文章介绍AITL的治疗进展。Angioimmunoblastic T-cell lymphoma （AITL） is a rare subtype of peripheral T-cell lymphoma （PTCL） with aggressive behaviour and poor prognosis. Due to the rarity of the disease, few prospective controlled randomized clinical trials were conducted,and the standard therapeutic option for AITL has not been established. Although conventional anthracycline-based chemotherapy achieves response rates of up to 50 %, most of the patients relapse, the median survival time and overall survival rate are unsatisfactory. Recent studies have demonstrated that hematopietic stem cell transplantation and cyclosporine show promising efficacy in the treatment of AITL. This current review mainly focused on the advance of treatment for AITL.

关 键 词：免疫母细胞淋巴结病 淋巴瘤 T细胞 造血干细胞移植 药物疗法 联合 

分 类 号：R733.1[医药卫生—肿瘤]